KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
This guideline cites 5 of the 58 landmark trials in our Nephrology register.
- Issued by
- KDIGO
- Year
- 2025
- Source
- Kidney Disease: Improving Global Outcomes (KDIGO) IgAN/IgAV Work Group. Kidney Int. 2025;108(4S):S1–S71.doi 10.1016/j.kint.2025.04.004
Published in September 2025, this is the first standalone KDIGO guideline for IgA nephropathy and IgA vasculitis, replacing the corresponding chapters of the 2021 glomerular-diseases guideline. It abandons the old 'optimise supportive care, then consider systemic steroids' sequence in favour of an early, risk-stratified use of disease-modifying therapy — targeted-release budesonide, dual endothelin/angiotensin-receptor antagonism and complement inhibition — layered on a supportive backbone that now explicitly includes an SGLT2 inhibitor. The register's supporting trials are grouped by treatment principle below.
Disease-modifying therapy2
- 2023NefIgArdNephrology · Glomerular · IgA nephropathyIn 364 patients with IgA nephropathy on optimised RAS blockade, targeted-release budesonide preserved eGFR and reduced proteinuria compared with placebo.Read →
- 2023PROTECT 2023Nephrology · Glomerular · IgA nephropathyIn 404 patients with IgA nephropathy and proteinuria despite maximal RAS blockade, sparsentan reduced proteinuria compared with irbesartan.-49.8% vs -15.1%Read →
Supportive care: SGLT2 inhibition2
- 2023EMPA-KIDNEYNephrology · CKD · SGLT2 inhibitorsIn 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.HR 0.7295% CI 0.64-0.82Read →
- 2020DAPA-CKD CoreNephrology · CKD · SGLT2 inhibitorsIn 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.HR 0.6195% CI 0.51-0.72Read →
Supportive care: RAS blockade & blood pressure1
- 1997REINNephrology · CKD · RAAS blockadeIn 352 patients with non-diabetic proteinuric chronic kidney disease, ramipril slowed GFR decline and progression to ESRD compared with placebo.Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2015STOP-IgAN
Adding immunosuppression to optimised supportive care did not preserve eGFR.
- 2022TESTING
Methylprednisolone slowed eGFR decline; the reduced-dose regimen improved the safety profile.
- 2017NEFIGAN
Phase-2 trial of targeted-release budesonide that led to NefIgArd.
- 2025ALIGN
Atrasentan, a selective endothelin-A antagonist, reduced proteinuria in IgA nephropathy.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.